Facial Injectables Market is expected to reach USD 17.2 billion by 2025

The global facial injectables market is expected to reach USD 17.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is expected to exhibit lucrative growth during the forecast period, owing to advancements in facial rejuvenation procedures and increasing importance of medical aesthetics across the globe.

Development in products & procedures, as well as change in patient demographics is helping dermatologists and physicians treat multiple facial areas. These advancements help dermatologists or physicians develop customized treatment for patients and facilitate use of combination products to obtain better outcomes. All these factors are expected to assist in the market growth over the forecast period. Augmented products such as Botulinum Toxin Type A (BoNTA) and Hyaluronic Acid (HA) fillers are used in combination to improve outcomes, especially in the lower face procedures. HA fillers are mostly preferred by physicians due to their better acceptance (few instances of hypersensitivity reactions), biodegradable nature, & high viscosity as well as for the longevity they provide to the restored volume.

Minimally invasive surgery, an advanced medical technology, is used for facial rejuvenation, endoscopy, laparoscopy, arthroscopy and other procedures. This procedure is gaining popularity over time owing to faster recovery, low instances of postsurgery infections, lower pain, reduced scarring, and high accuracy & maximum benefits. For instance, as per International Society of Aesthetic Plastic Surgery (ISAPS), more than 20.0 million surgical and nonsurgical cosmetic procedures were performed worldwide in 2014.The number of HA-based surgeries performed in 2014 was 2,690,633, which increased to 2,865,086 in 2015, which is thereby expected to contribute to the growth of this space over the forecast period.